



CLAIMS

1. Pyridinylpyrazolopyrimidinone derivative represented by the following formula (IA) or (IB):



wherein:

R¹ is substituted or unsubstituted C₃-C₈ cycloalkyl group or tert-butyl group;

R² is a hydrogen atom or C₁-C₃ alkyl group;

R³ is a group: -NR⁵R⁶, -C(=O)R⁷ or -S(O)₀₋₂R⁸;

R⁴ is a hydrogen atom or C₁-C₃ alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s);

R⁵ and R⁶ are, same or different from each other, a hydrogen atom, substituted or unsubstituted C₁-C₆ alkyl group, substituted or unsubstituted acyl group, substituted or unsubstituted heterocycloalkyl group, and substituted or unsubstituted heterocycloalkyl ring is formed with nitrogen atom which is binding R⁵ and R⁶;

R⁷ is a group: -OR⁹ or -NR⁵R⁶;

R⁸ is a hydrogen atom, a halogen atom, a group: -NR⁵R⁶, substituted or unsubstituted C₁-C₆ alkyl group, or substituted or unsubstituted aryl group;

R⁹ is a hydrogen atom or substituted or unsubstituted C₁-C₆ alkyl group;

or pharmaceutically acceptable salts or solvates thereof.

2. The compound represented by the formula (IA) according to claim 1.

3. The compound represented by the formula (IB) according to claim 1.

4. The compound according to claim 1, 2 or 3, in which R¹ is

cyclohexyl group or cycloheptyl group.

5. The compound according to any one of claims 1 to 4, in which R^2 is methyl group.

6. The compound according to any one of claims 1 to 5, in which
5 R^4 is methoxy or ethoxy group.

7. The compound according to any one of claims 1 to 6, in which R^3 is a group $-NR^5R^6$.

8. A pharmaceutical composition containing a compound according to any one of claims 1 to 7, or pharmaceutically acceptable salts or solvates
10 thereof as active ingredient.

9. A PDE 7 inhibitor containing a compound according to any one of claims 1 to 7, or pharmaceutically acceptable salts or solvates thereof as active ingredient.